The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.
CMS introduced the first wave of interoperable digital solutions to improve patient experiences and enhance care delivery as part of the agency’s HealthTech Ecosystem initiative.
Forbes contributors publish independent expert analyses and insights. Diane Omdahl is a Medicare expert who keeps her readers in the know. On December 23, the Centers for Medicare and Medicaid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results